The European Commission has authorized the marketing of the drug “Tizild,” which slows the progression of type 1 diabetes, within the European Union, according to an announcement by the French company (Sanofi), the drug’s manufacturer. The company said in a statement that this license makes Tizeld the first treatment that affects the progression of type 1 diabetes to receive formal approval in the European Union. The approval includes...